国药控股 (HKSE:01099)
HK$19.42
▼-0.42(
-2.12%)
0.74
市净率
7.38
市盈率
4.64
股息率 ％
HK$606亿
总市值
股价被低估
检测到3个危险信号,
点击订阅查看详情
价值大师评分 :
0
/100
1月
3月
6月
今年
1年
3年
5年
10年
15年
全部
3年:0%
国药控股 内部交易概览
最近18个月交易的高管股东 | 交易次数 | 净买入（股） |
|---|---|---|
| Fmr Llc | 5 | -679,043 |
| JPMorgan Chase & Co. | 4 | 18,913,898 |
| BlackRock, Inc. | 2 | 23,768,175 |
| Lazard Asset Management LLC | 1 | 414,800 |
| Citigroup Inc. | 0 | 0 |
交易分段汇总 | 买入数量 | 卖出数量 | 净买入（股） |
|---|---|---|---|
| 最近1个月 | 0 | 0 | 0 |
| 最近3个月 | 3,770,263 | 0 | 3,770,263 |
| 最近6个月 | 3,770,263 | 1,705,443 | 2,064,820 |
| 最近12个月 | 27,910,073 | 1,705,443 | 26,204,630 |
| 最近18个月 | 44,421,673 | 2,003,843 | 42,417,830 |
| 最近36个月 | 44,421,673 | 2,003,843 | 42,417,830 |
国药控股 内部交易
今年
1年
3年
5年
10年
15年
全部
国药控股 最新内部交易
Fmr Llc | 2201 Interest of corporation controlled by you | 2024-04-02 | 买入 | 997,600 | 161,576,874 |
HK$20.49
|
-5.22%
|
JPMorgan Chase & Co. | 2502 Approved lending agent | 2024-02-08 | - | 216,125 | 80,327,054 |
HK$21.55
|
-9.88%
|
JPMorgan Chase & Co. | 2201 Interest of corporation controlled by you | 2024-02-05 | 买入 | 2,772,663 | 82,601,175 |
HK$20.49
|
-5.22%
|
BlackRock, Inc. | 2201 Interest of corporation controlled by you | 2024-01-10 | - | 1,162,022 | 93,148,465 |
HK$0
|
--
|
BlackRock, Inc. | 2201 Interest of corporation controlled by you | 2024-01-09 | - | 2,254,114 | 94,339,117 |
HK$0
|
--
|
BlackRock, Inc. | 2201 Interest of corporation controlled by you | 2023-12-12 | - | 2,254,285 | 92,365,213 |
HK$0
|
--
|
BlackRock, Inc. | 2201 Interest of corporation controlled by you | 2023-12-11 | - | 6,038,499 | 94,649,098 |
HK$0
|
--
|
Fmr Llc | 2201 Interest of corporation controlled by you | 2023-11-10 | 卖出 | 1,705,443 | 160,276,364 |
HK$0
|
--
|
JPMorgan Chase & Co. | 2502 Approved lending agent | 2023-11-06 | - | 1,046,021 | 80,359,885 |
HK$19.43
|
-0.05%
|
JPMorgan Chase & Co. | 2102 Investment manager | 2023-10-31 | - | 4,125,463 | 82,158,632 |
HK$18.49
|
+5.03%
|